companies / orbismedicines-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-06-07 json
| total_raised | 28,080,00028.1M | ○ |
|---|---|---|
| founded | 2022 | |
| hq | Copenhagen, Denmark | |
| industry | unknown | |
| stage | seed |
Orbis Medicines develops oral macrocycle drugs via its nGen platform, designing compounds called nCycles to turn injectable biologics into pills. It serves patients on biologic therapies and pharma partners seeking oral alternatives. A single design-make-test cycle generates up to 100,000 target-specific nCycles.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-02-01 | seed | 28,080,00028.1M | null | ○ |
@sentry/browser, adobe fonts, afterpay, hsts, moment 0, parallax.js, squarespace, squarespace commerce, stimulus, typekit, web-vitals
| fact | status | src |
|---|---|---|
| Seed, $28.1M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |